Literature DB >> 20304997

Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity.

Lawrence S Argetsinger1, Jeanne A Stuckey, Scott A Robertson, Rositsa I Koleva, Joel M Cline, Jarrod A Marto, Martin G Myers, Christin Carter-Su.   

Abstract

Janus kinase 2 (JAK2) is activated by a majority of cytokine family receptors including receptors for GH, leptin, and erythropoietin. To identify novel JAK2-regulatory and/or -binding sites, we set out to identify autophosphorylation sites in the kinase domain of JAK2. Two-dimensional phosphopeptide mapping of in vitro autophosphorylated JAK2 identified tyrosines 868, 966, and 972 as sites of autophosphorylation. Phosphorylated tyrosines 868 and 972 were also identified by mass spectrometry analysis of JAK2 activated by an erythropoietin-bound chimeric erythropoietin receptor/leptin receptor. Phosphospecific antibodies suggest that the phosphorylation of all three tyrosines increases in response to GH. Compared with wild-type JAK2, which is constitutively active when overexpressed, JAK2 lacking tyrosine 868, 966, or 972 has substantially reduced activity. Coexpression with GH receptor and protein tyrosine phosphatase1B allowed us to investigate GH-dependent activation of these mutated JAK2s in human embryonic kidney 293T cells. All three mutated JAK2s are activated by GH, although to a lesser extent than wild-type JAK2. The three mutated JAK2s also mediate GH activation of signal transducer and activator of transcription 3 (Stat3), signal transducer and activator of transcription 5b (Stat5b) and ERK1, but at reduced levels. Coexpression with Src-homology 2B1beta (SH2B1beta), like coexpression with GH-bound GH receptor, partially restores the activity of all three JAK2 mutants. Based on these results and the crystal structure of the JAK2 kinase domain, we hypothesize that small changes in the conformation of the regions of JAK2 surrounding tyrosines 868, 966, and 972 due to e.g. phosphorylation, binding to a ligand-bound cytokine receptor, and/or binding to Src-homology 2B1, may be essential for JAK2 to assume a maximally active conformation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304997      PMCID: PMC2870937          DOI: 10.1210/me.2009-0355

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  54 in total

1.  Multiple in vivo tyrosine phosphorylation sites in EphB receptors.

Authors:  M S Kalo; E B Pasquale
Journal:  Biochemistry       Date:  1999-10-26       Impact factor: 3.162

Review 2.  The conformational plasticity of protein kinases.

Authors:  Morgan Huse; John Kuriyan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

3.  Regulation of Jak kinases by intracellular leptin receptor sequences.

Authors:  Carolyn Kloek; Asma K Haq; Sarah L Dunn; Hugh J Lavery; Alexander S Banks; Martin G Myers
Journal:  J Biol Chem       Date:  2002-08-23       Impact factor: 5.157

4.  Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/multiple reaction monitoring mass spectrometry.

Authors:  Eugene Ciccimaro; John Hevko; Ian A Blair
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

5.  A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases.

Authors:  Silke Wiesner; Leanne E Wybenga-Groot; Neil Warner; Hong Lin; Tony Pawson; Julie D Forman-Kay; Frank Sicheri
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

6.  In vivo tyrosine phosphorylation sites of activated ephrin-B1 and ephB2 from neural tissue.

Authors:  M S Kalo; H H Yu; E B Pasquale
Journal:  J Biol Chem       Date:  2001-07-20       Impact factor: 5.157

7.  Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2.

Authors:  Megumi Funakoshi-Tago; Stephane Pelletier; Tadashi Matsuda; Evan Parganas; James N Ihle
Journal:  EMBO J       Date:  2006-10-05       Impact factor: 11.598

8.  The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.

Authors:  Isabelle S Lucet; Emmanuelle Fantino; Michelle Styles; Rebecca Bamert; Onisha Patel; Sophie E Broughton; Mark Walter; Christopher J Burns; Herbert Treutlein; Andrew F Wilks; Jamie Rossjohn
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

9.  Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B.

Authors:  Jang Hyun Choi; Hyeon Soo Kim; Sun-Hee Kim; Yong Ryoul Yang; Yun Soo Bae; Jong-Soo Chang; H Moo Kwon; Sung Ho Ryu; Pann-Ghill Suh
Journal:  Nat Cell Biol       Date:  2006-11-26       Impact factor: 28.824

10.  Activation of downstream signals by the long form of the leptin receptor.

Authors:  A S Banks; S M Davis; S H Bates; M G Myers
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

View more
  12 in total

1.  Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.

Authors:  Maria-Elena Liosi; Stefan G Krimmer; Ana S Newton; Thomas K Dawson; David E Puleo; Kara J Cutrona; Yoshihisa Suzuki; Joseph Schlessinger; William L Jorgensen
Journal:  J Med Chem       Date:  2020-05-08       Impact factor: 7.446

2.  Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation.

Authors:  Jacqueline Sayyah; Kavitha Gnanasambandan; Sushama Kamarajugadda; Shigeharu Tsuda; Jennifer Caldwell-Busby; Peter P Sayeski
Journal:  Cell Signal       Date:  2011-06-29       Impact factor: 4.315

3.  The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.

Authors:  Daniela Ungureanu; Jinhua Wu; Tuija Pekkala; Yashavanthi Niranjan; Clifford Young; Ole N Jensen; Chong-Feng Xu; Thomas A Neubert; Radek C Skoda; Stevan R Hubbard; Olli Silvennoinen
Journal:  Nat Struct Mol Biol       Date:  2011-08-14       Impact factor: 15.369

4.  Identification of steroid-sensitive gene-1/Ccdc80 as a JAK2-binding protein.

Authors:  Erin E O'Leary; Anna M Mazurkiewicz-Muñoz; Lawrence S Argetsinger; Travis J Maures; Hung T Huynh; Christin Carter-Su
Journal:  Mol Endocrinol       Date:  2013-02-28

Review 5.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

6.  Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

Review 7.  Structure, production and signaling of leptin.

Authors:  Heike Münzberg; Christopher D Morrison
Journal:  Metabolism       Date:  2014-09-28       Impact factor: 8.694

8.  The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway.

Authors:  Jiaqi Wang; Yi Zhang; Hu Song; Hang Yin; Tao Jiang; Yixin Xu; Lianyu Liu; Hongyu Wang; Hong Gao; Renhao Wang; Jun Song
Journal:  Mol Cancer       Date:  2021-06-01       Impact factor: 27.401

9.  Research resource: identification of novel growth hormone-regulated phosphorylation sites by quantitative phosphoproteomics.

Authors:  Bridgette N Ray; Hye Kyong Kweon; Lawrence S Argetsinger; Diane C Fingar; Philip C Andrews; Christin Carter-Su
Journal:  Mol Endocrinol       Date:  2012-05-08

Review 10.  A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors.

Authors:  Michael J Waters; Andrew J Brooks; Yash Chhabra
Journal:  JAKSTAT       Date:  2014-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.